What do biomarkers like EGFR or KRAS mean for treatment

What Biomarkers Like EGFR or KRAS Mean for Treatment

Biomarkers are molecular "signatures" in your tumor—specific mutations or proteins that tell doctors how your cancer behaves and which drugs might work best against it.

How They Work

EGFR and KRAS are genes that normally control cell growth. When mutated in cancer cells, they drive tumor growth in specific ways. Finding these mutations is like identifying the tumor's weak point.

Treatment Connection

According to NCCN Guidelines, once a biomarker is identified, doctors can match it to FDA-approved drugs designed to target it:

• EGFR mutations → EGFR inhibitors (drugs that block this specific pathway)
• KRAS mutations → Targeted therapies now available for certain KRAS variants
• Other mutations (BRCA, HRR genes, MSI-H) → PARP inhibitors, immunotherapies, or other precision drugs

Why It Matters

As described in Cancer Commons' precision medicine resources, biomarkers help answer: "Will this specific drug work for my tumor?" Rather than guessing, your oncologist can see the molecular evidence.

Important caveat: Having a mutation doesn't guarantee response—other factors (co-occurring mutations, tumor heterogeneity, prior treatments) affect outcomes. But biomarkers significantly narrow the field and identify options that wouldn't be considered otherwise.

Next Step

Ask your oncologist: "What biomarkers has my tumor been tested for, and what treatment options do they suggest?"

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.